Merck Inc. is locking horns with peer Pfizer Inc. in what could be termed as the battle supremacy in the COVID-19 treatment market.
The stakes are high, with an effective treatment for the disease potentially entering the arena in addition to the vaccines that are already on the market.
Pfizer Dips Into COVID-19 Treatment Arena
After moving ahead in the COVID-19 vaccine race along with its German partner BioNTech SE, Pfizer is wanting to leave no stone unturned in capitalizing on the COVID-19 opportunity.
